recombinant factor viia also known eptacog alfa inn sold brand name novoseven among others form blood factor vii manufactured via recombinant administered via injection common side effects novoseven include venous thromboembolic events problems caused blood clots veins rash pruritus itching urticaria hives fever reduced effectiveness common side effects cevenfacta include injection site discomfort hematoma collection blood skin well injectionrelated reactions increase body temperature dizziness novoseven approved medical use european union february united states march novoseven rt approved medical use us may novoseven indicated treatment bleeding episodes prevention bleeding surgical interventions invasive procedures people acquired novoseven rt indicated treatment bleeding episodes perioperative management adults children hemophilia b inhibitors congenital factor vii deficiency glanzmanns thrombasthenia refractoriness platelet transfusions without antibodies platelets treatment bleeding episodes perioperative management adults acquired sevenfact coagulation factor viia recombinantjncw approved use united states indicated treatment control bleeding episodes occurring adults adolescents twelve years age older hemophilia b inhibitors neutralizing recombinant factor viia supported evidence treating cases major significant risk arterial thrombosis use thus factor vii deficiency given clinical recombinant human factor vii initially looking promising intracerebral hemorrhage failed show benefit following study longer people hemophilia type b deficiency factors viii ix two factors administered controlling bleeding prophylaxis medication starting surgeries however cases subsequently develop neutralizing antibodies called inhibitors drug inhibitors often increase time inhibit action coagulation body recombinant factor viia activated form factor vii bypasses factors viii ix causes coagulation without need factors viii ix cant given without inhibitorcitation needed important patients shift proper blood factors according inhibitor titer indications include use patients acquired hemophilia people born deficiency factor vii people glanzmanns treatment results activation extrinsic pathway blood coagulation factor viia recombinantjncw sevenfact expressed mammary gland genetically engineered rabbits secreted rabbits milk purification processing milk fvii converted activated fvii recombinant dna rdna construct genetically engineered rabbits used production sevenfact approved fdas center veterinary safety efficacy coagulation factor viia recombinantjncw determined using data clinical study evaluated patients hemophilia b inhibitors included treatment mild moderate three severe bleeding study assessed efficacy treatment twelve hours initial dose proportion mild moderate bleeding episodes treated successfully lower dose higher dose mcgkg requiring treatment bleeding episode administration blood products increase pain beyond hours initial dose approximately study also included three severe bleeding episodes treated successfully higher another study evaluated safety pharmacokinetics three escalating doses coagulation factor viia recombinantjncw subjects severe hemophilia b without results study used select two doses mcgkg evaluated study described common side effects coagulation factor viia recombinantjncw headache dizziness infusion site discomfort infusion related reaction infusion site hematoma coagulation factor viia recombinantjncw contraindicated known allergy hypersensitivity rabbits rabbit novoseven approved use united states march indicated treatment bleeding episodes hemophilia b patients inhibitors factor viii factor approved october indicated treatment bleeding episodes prevention bleeding surgical interventions invasive procedures patients acquired novoseven rt approved use united states may roomtemperature stable january label updated include boxed warning serious thrombotic adverse events associated use novoseven rt outside labeled april coagulation factor viia recombinantjncw sevenfact approved use united may committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product cevenfacta intended treatment bleeding applicant medicinal product laboratoire fran√ßais du fractionnement et des biotechnologies active substance cevenfacta eptacog beta activated blood coagulation factor atc code eptacog beta almost identical functions like coagulation factor activates factor x starts clotting process thereby provides control factor vii acts directly factor x independently factors viii ix cevenfacta used restore haemostasis absence presence cevenfacta approved medical use european union july rfviia used routinely severely wounded american troops iraq war credited saving many lives also resulting high number deep venous thromboses pulmonary emboli well unexpected strokes heart attacks httpsenwikipediaorgwikirecombinantfactorviia